Earnings call transcript: ResMed surpasses Q2 FY2025 expectations, stock dips
ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...
HME News23h
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
Investor's Business Daily on MSN23h
ResMed, In A Buy Zone, Whipsaws Despite Strong Profit Beat
ResMed stock whipsawed Thursday after the CPAP maker reported better-than-expected December-quarter profit and narrowly beat sales forecasts. Please watch the video at Investors.com - How To Buy ...
MassDevice23h
ResMed revenue up 10% in Q2 — but GLP-1 questions remain
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...